通过通过脱甲基化以m6A依赖的方式调节MAP4K4表达,FTO促进胃癌的进展
Zhe Yin1,2, Xiong Guo1, Xiaolong Liang1
1Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Medical oncology (Northwood, London, England)
|April 20, 2024
概括
高水平的FTO (N6-甲基氨酸修饰的关键调节剂) 与胃癌的预后不佳相关. FTO促进癌细胞的生长和扩散,提供新的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 胃癌 (GC) 由于其高死亡率和患者表现不佳而构成重大全球健康挑战.
- N6-甲基氨酸 (m6A) 修饰因其在调节癌症发展中的作用而越来越受认可.
- 在胃癌中m6A脱甲基酶FTO的特定功能在很大程度上仍未定义.
研究的目的:
- 为了研究胃癌中FTO的表达模式.
- 阐明FTO在GC进展中的功能作用和潜在的分子机制.
- 评估FTO在胃癌患者的预后价值.
主要方法:
- 分析TCGA-STAD数据集的FTO表达和与临床病理参数的相关性.
- 使用qRT-PCR,免疫组织化学和西部涂抹验证FTO表达的验证.
- 功能测试包括CCK-8,EDU,流细胞计和Transwell测试,以评估细胞行为.
- 通过转录组测序和RNA免疫沉来探索分子机制.
主要成果:
- 与正常对照组相比,FTO在GC组织和细胞中显著上调.
- 高FTO表达与更差的预后和先进的临床病理特征有关.
- 过度表达FTO促进了GC细胞的增殖,迁移和入侵,同时抑制了亡.
- 通过对MAP4K4表达进行上调,FTO促进了GC的进展.
结论:
- FTO是胃癌的致癌因素,促进瘤的进展,并预测预后不佳.
- 通过FTO介导的m6A脱甲基化通过涉及MAP4K4.4的途径影响GC发育.
- 准FTO可能代表胃癌管理的新疗法策略.
更多相关视频
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.5K
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.1K
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
01:07MAPK Signaling Cascades
5.5K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.5K
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K